Acrobiosystems for English
icon_bulk_orderConsulta masiva/Pedido rápido
user
  1. Cuadro de mandos
  2. Mi perfil
  3. Mi dirección
  4. Mis pedidos
  5. Afiliación a Acro
Iniciar sesión Registro
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
No hay productos en el carro de la compra
Mi carro|Check Out
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Su posición : Casa > Insights > Top targets of cell therapy for haematological malignancies
Top targets of cell therapy for haematological malignancies
Release time: 2021-09-17 Source: ACROBiosystems Read: 4465
1.png

Till April, 2021, according to the data published on ClinicalTrials.gov, there are 1,358 active cell therapy trials, among which most trials are focusing on haematological malignancies, Typical targets include CD19, BCMA and CD22.

ACROBiosystems offers a series of CAR-T target proteins for haematological tumor, such as CD19, BCMA, CD20, CD30 products, which are suitable for detecting CAR expression in clinical trials.


Haematological tumor targets at ACROBiosystems
BCMA HOT CD123 CD19 HOT  CD20CD30 CD37 CD38 CD4 CD5 CD7 HOT CD72 CD8 alpha CD8 alpha & beta CLEC12A FMC63 GPRC5D HOT Siglec-2 Siglec-3 SLAMF7 Syndecan-1

More CAR-T targets >>>

Product Data
Detection of Anti-CD19 CAR Expression by FACS

  • Cat. No. CD9-HP2H3

  • 6.jpg


    • 1e6 of the anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HP2H3). PE Streptavidin was used as negative control.
FACS Analysis of Anti-CD22 CAR Expression

  • Cat. No. SI2-HF2H6

  • 3.jpg

    • 293 cells were transfected with anti-CD22-scFv and RFP tag. 2e5 of the cells were stained with FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6, 10 µg/mL) and FITC-labeled Protein Control. Non-transfected 293 cells and FITC-labeled Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD22-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6).

More CAR-T related products

>  Click here to learn more about blood tumor targets

>  Click here to learn more about Fluorescent-labeled proteins

>  Click here to learn more about CD19 targets

Prev
Next

This web search service is supported by Google Inc.

totop
Call us
Call us

Germany+49 800 0826645

United Kingdom+44 808 281 3436

Netherlands+31 800 0224992

Switzerland+41 800 040 012

France+33 800 90 78 85

Sweden+46 20 12 76 94

Denmark+45 80 83 07 62

Belgium+32 800 27 125

Email
Correo electrónico
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland
linkedin twitter facebook youtube

Dejar un mensaje

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap